- Home
- GRNT vs CGEM Comparison
GRNT vs CGEM Comparison
Compare GRNT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNT
- CGEM
- Stock Information
- Founded
- GRNT 2013
- CGEM 2016
- Country
- GRNT United States
- CGEM United States
- Employees
- GRNT N/A
- CGEM N/A
- Industry
- GRNT Blank Checks
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- GRNT Finance
- CGEM Health Care
- Exchange
- GRNT Nasdaq
- CGEM Nasdaq
- Market Cap
- GRNT 752.6M
- CGEM 530.0M
- IPO Year
- GRNT N/A
- CGEM 2021
- Fundamental
- Price
- GRNT $6.07
- CGEM $7.53
- Analyst Decision
- GRNT Buy
- CGEM Strong Buy
- Analyst Count
- GRNT 2
- CGEM 5
- Target Price
- GRNT $7.50
- CGEM $30.00
- AVG Volume (30 Days)
- GRNT 987.1K
- CGEM 354.7K
- Earning Date
- GRNT 08-07-2025
- CGEM 08-07-2025
- Dividend Yield
- GRNT 7.22%
- CGEM N/A
- EPS Growth
- GRNT N/A
- CGEM N/A
- EPS
- GRNT 0.09
- CGEM N/A
- Revenue
- GRNT $390,665,000.00
- CGEM N/A
- Revenue This Year
- GRNT $30.32
- CGEM N/A
- Revenue Next Year
- GRNT $7.79
- CGEM N/A
- P/E Ratio
- GRNT $67.58
- CGEM N/A
- Revenue Growth
- GRNT 6.26
- CGEM N/A
- 52 Week Low
- GRNT $4.52
- CGEM $6.85
- 52 Week High
- GRNT $7.10
- CGEM $21.01
- Technical
- Relative Strength Index (RSI)
- GRNT 49.40
- CGEM 40.12
- Support Level
- GRNT $6.00
- CGEM $7.29
- Resistance Level
- GRNT $6.72
- CGEM $8.05
- Average True Range (ATR)
- GRNT 0.20
- CGEM 0.42
- MACD
- GRNT -0.06
- CGEM -0.07
- Stochastic Oscillator
- GRNT 10.96
- CGEM 17.48
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.